Reviewing 60 Degrees Pharmaceuticals (SXTP) and Its Peers

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is one of 1,004 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare 60 Degrees Pharmaceuticals to related businesses based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Valuation & Earnings

This table compares 60 Degrees Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$352,864.00	-$3.77 million	-0.24
60 Degrees Pharmaceuticals Competitors	$1.68 billion	$153.43 million	-2.98

60 Degrees Pharmaceuticals’ competitors have higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings for 60 Degrees Pharmaceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	0	1	1	0	2.50
60 Degrees Pharmaceuticals Competitors	6701	19249	45708	970	2.56

60 Degrees Pharmaceuticals presently has a consensus price target of $2.40, suggesting a potential upside of 848.99%. As a group, “Pharmaceutical preparations” companies have a potential upside of 74.88%. Given 60 Degrees Pharmaceuticals’ higher possible upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than its competitors.

Insider & Institutional Ownership

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares 60 Degrees Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	N/A	N/A	-78.95%
60 Degrees Pharmaceuticals Competitors	-2,992.57%	-287.70%	-33.64%

Summary

60 Degrees Pharmaceuticals competitors beat 60 Degrees Pharmaceuticals on 8 of the 12 factors compared.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.